Click for best price
Nonalcoholic Steatohepatitis NASH Market Size, Share 2024
| Market size in 2023 |
US$ 2890.1 million
|
Forecast Market size by 2030 |
US$ 48190 million
|
| Growth Rate |
CAGR of 49.2% |
Number of Pages |
108 Pages |
This research report provides a comprehensive analysis of the Nonalcoholic Steatohepatitis (NASH) market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Nonalcoholic Steatohepatitis (NASH) market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Nonalcoholic Steatohepatitis (NASH), challenges faced by the industry, and potential opportunities for market players.
The global Nonalcoholic Steatohepatitis (NASH) market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Nonalcoholic Steatohepatitis (NASH) market presents opportunities for various stakeholders, including Hospital Pharmacy, Online Provider. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Nonalcoholic Steatohepatitis (NASH) market. Additionally, the growing consumer demand present avenues for market expansion.
The global Nonalcoholic Steatohepatitis (NASH) market was valued at US$ 2890.1 million in 2023 and is projected to reach US$ 48190 million by 2030, at a CAGR of 49.2% during the forecast period.
Non-alcoholic drinks, also known as mocktails or alcohol-free beverages, are beverages that do not contain any alcohol. These drinks are a popular choice for those who do not consume alcohol, including designated drivers, people who are underage, or individuals who wish to avoid alcohol for personal or health reasons. There are a wide variety of non-alcoholic drinks available, ranging from soft drinks to fresh juices, herbal infusions, and specialty mocktails. Some examples of non-alcoholic drinks include: 1. Soft Drinks: This category includes popular carbonated beverages like cola, lemon-lime sodas, ginger ale, and root beer. These drinks are often sweet and fizzy, providing a refreshing and enjoyable beverage option. 2. Fruit Juices: Freshly squeezed or packaged fruit juices, such as orange, apple, grapefruit, pineapple, or cranberry juice, are a common choice. These juices offer a natural and flavorful alternative to alcoholic beverages. 3. Smoothies: Made from a blend of fruits, vegetables, yogurt, and other ingredients, smoothies provide a nutritious and wholesome non-alcoholic option. They can be customized with various flavors and ingredients to suit individual preferences. 4. Herbal Infusions and Tea: Herbal teas and infusions, such as chamomile, peppermint, green tea, or hibiscus tea, are popular choices. These beverages are caffeine-free and often have relaxing or soothing properties. 5. Mocktails: These are non-alcoholic cocktails that mimic the flavors and presentation of traditional cocktails. They are typically made with a combination of juices, sodas, and garnishes, providing a fancy and enjoyable experience without the alcohol. 6. Sparkling Water: Carbonated water or mineral water with added flavors or fruit infusions is a refreshing and hydrating option. It is often consumed plain or mixed with juices or syrups. These non-alcoholic drinks offer a variety of flavors, textures, and options for those who prefer not to consume alcohol. They are a great way to enjoy a beverage while socializing or relaxing without the effects of alcohol.
Key Features:
The research report on the Nonalcoholic Steatohepatitis (NASH) market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Nonalcoholic Steatohepatitis (NASH) market.
Market Overview: The report provides a comprehensive overview of the Nonalcoholic Steatohepatitis (NASH) market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Obeticholic acid?OCA?, Selonsertib), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Nonalcoholic Steatohepatitis (NASH) market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Nonalcoholic Steatohepatitis (NASH) market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Nonalcoholic Steatohepatitis (NASH) market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Nonalcoholic Steatohepatitis (NASH) market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Nonalcoholic Steatohepatitis (NASH) market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Nonalcoholic Steatohepatitis (NASH) market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Nonalcoholic Steatohepatitis (NASH), including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Nonalcoholic Steatohepatitis (NASH) market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
- Nonalcoholic Steatohepatitis (NASH) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Obeticholic acid?OCA?
- Selonsertib
Market segment by Application
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
Global Nonalcoholic Steatohepatitis (NASH) Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- AstraZeneca
- Arena Pharmaceuticals
- GSK
- Novo Nordisk
- Roche
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
Outline of Major Chapters:
Chapter 1: Introduces the definition of Nonalcoholic Steatohepatitis (NASH), market overview.
Chapter 2: Global Nonalcoholic Steatohepatitis (NASH) market size in revenue.
Chapter 3: Detailed analysis of Nonalcoholic Steatohepatitis (NASH) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nonalcoholic Steatohepatitis (NASH) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Nonalcoholic Steatohepatitis (NASH) Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 2890.1 million
|
| Forecast Market size by 2030 |
US$ 48190 million
|
| Growth Rate |
CAGR of 49.2% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
108 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Nonalcoholic Steatohepatitis (NASH) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Nonalcoholic Steatohepatitis (NASH) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Nonalcoholic Steatohepatitis (NASH) Overall Market Size
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size: 2023 VS 2030
2.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Nonalcoholic Steatohepatitis (NASH) Players in Global Market
3.2 Top Global Nonalcoholic Steatohepatitis (NASH) Companies Ranked by Revenue
3.3 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Companies
3.4 Top 3 and Top 5 Nonalcoholic Steatohepatitis (NASH) Companies in Global Market, by Revenue in 2023
3.5 Global Companies Nonalcoholic Steatohepatitis (NASH) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Nonalcoholic Steatohepatitis (NASH) Players in Global Market
3.6.1 List of Global Tier 1 Nonalcoholic Steatohepatitis (NASH) Companies
3.6.2 List of Global Tier 2 and Tier 3 Nonalcoholic Steatohepatitis (NASH) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Nonalcoholic Steatohepatitis (NASH) Market Size Markets, 2023 & 2030
4.1.2 Obeticholic acid?OCA?
4.1.3 Selonsertib
4.2 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue & Forecasts
4.2.1 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2024
4.2.2 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2025-2030
4.2.3 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Nonalcoholic Steatohepatitis (NASH) Market Size, 2023 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Online Provider
5.1.4 Retail Pharmacy
5.2 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue & Forecasts
5.2.1 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2024
5.2.2 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2025-2030
5.2.3 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Nonalcoholic Steatohepatitis (NASH) Market Size, 2023 & 2030
6.2 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue & Forecasts
6.2.1 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2024
6.2.2 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2025-2030
6.2.3 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2030
6.3.2 US Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.3.3 Canada Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.3.4 Mexico Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2030
6.4.2 Germany Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4.3 France Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4.4 U.K. Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4.5 Italy Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4.6 Russia Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4.7 Nordic Countries Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.4.8 Benelux Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2030
6.5.2 China Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.5.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.5.4 South Korea Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.5.5 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.5.6 India Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2030
6.6.2 Brazil Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.6.3 Argentina Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2030
6.7.2 Turkey Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.7.3 Israel Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.7.4 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
6.7.5 UAE Nonalcoholic Steatohepatitis (NASH) Market Size, 2019-2030
7 Nonalcoholic Steatohepatitis (NASH) Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.1.4 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Arena Pharmaceuticals
7.2.1 Arena Pharmaceuticals Company Summary
7.2.2 Arena Pharmaceuticals Business Overview
7.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.2.5 Arena Pharmaceuticals Key News & Latest Developments
7.3 GSK
7.3.1 GSK Company Summary
7.3.2 GSK Business Overview
7.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.3.4 GSK Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.3.5 GSK Key News & Latest Developments
7.4 Novo Nordisk
7.4.1 Novo Nordisk Company Summary
7.4.2 Novo Nordisk Business Overview
7.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.4.4 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.4.5 Novo Nordisk Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.5.4 Roche Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.5.5 Roche Key News & Latest Developments
7.6 Vivus
7.6.1 Vivus Company Summary
7.6.2 Vivus Business Overview
7.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.6.4 Vivus Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.6.5 Vivus Key News & Latest Developments
7.7 Arisaph Pharmaceuticals
7.7.1 Arisaph Pharmaceuticals Company Summary
7.7.2 Arisaph Pharmaceuticals Business Overview
7.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.7.5 Arisaph Pharmaceuticals Key News & Latest Developments
7.8 Cempra Pharmaceuticals
7.8.1 Cempra Pharmaceuticals Company Summary
7.8.2 Cempra Pharmaceuticals Business Overview
7.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.8.5 Cempra Pharmaceuticals Key News & Latest Developments
7.9 Galectin Therapeutics
7.9.1 Galectin Therapeutics Company Summary
7.9.2 Galectin Therapeutics Business Overview
7.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.9.5 Galectin Therapeutics Key News & Latest Developments
7.10 Galmed Pharmaceuticals
7.10.1 Galmed Pharmaceuticals Company Summary
7.10.2 Galmed Pharmaceuticals Business Overview
7.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.10.5 Galmed Pharmaceuticals Key News & Latest Developments
7.11 Genfit
7.11.1 Genfit Company Summary
7.11.2 Genfit Business Overview
7.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.11.4 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.11.5 Genfit Key News & Latest Developments
7.12 Gilead
7.12.1 Gilead Company Summary
7.12.2 Gilead Business Overview
7.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.12.4 Gilead Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2019-2024)
7.12.5 Gilead Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Nonalcoholic Steatohepatitis (NASH) Market Opportunities & Trends in Global Market
Table 2. Nonalcoholic Steatohepatitis (NASH) Market Drivers in Global Market
Table 3. Nonalcoholic Steatohepatitis (NASH) Market Restraints in Global Market
Table 4. Key Players of Nonalcoholic Steatohepatitis (NASH) in Global Market
Table 5. Top Nonalcoholic Steatohepatitis (NASH) Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Companies, 2019-2024
Table 8. Global Companies Nonalcoholic Steatohepatitis (NASH) Product Type
Table 9. List of Global Tier 1 Nonalcoholic Steatohepatitis (NASH) Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Nonalcoholic Steatohepatitis (NASH) Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2025-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 32. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Arena Pharmaceuticals Company Summary
Table 35. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 36. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 37. Arena Pharmaceuticals Key News & Latest Developments
Table 38. GSK Company Summary
Table 39. GSK Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 40. GSK Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 41. GSK Key News & Latest Developments
Table 42. Novo Nordisk Company Summary
Table 43. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 44. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 45. Novo Nordisk Key News & Latest Developments
Table 46. Roche Company Summary
Table 47. Roche Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 48. Roche Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 49. Roche Key News & Latest Developments
Table 50. Vivus Company Summary
Table 51. Vivus Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 52. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 53. Vivus Key News & Latest Developments
Table 54. Arisaph Pharmaceuticals Company Summary
Table 55. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 56. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 57. Arisaph Pharmaceuticals Key News & Latest Developments
Table 58. Cempra Pharmaceuticals Company Summary
Table 59. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 60. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 61. Cempra Pharmaceuticals Key News & Latest Developments
Table 62. Galectin Therapeutics Company Summary
Table 63. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 64. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 65. Galectin Therapeutics Key News & Latest Developments
Table 66. Galmed Pharmaceuticals Company Summary
Table 67. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 68. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 69. Galmed Pharmaceuticals Key News & Latest Developments
Table 70. Genfit Company Summary
Table 71. Genfit Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 72. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 73. Genfit Key News & Latest Developments
Table 74. Gilead Company Summary
Table 75. Gilead Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 76. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2019-2024)
Table 77. Gilead Key News & Latest Developments
List of Figures
Figure 1. Nonalcoholic Steatohepatitis (NASH) Segment by Type in 2023
Figure 2. Nonalcoholic Steatohepatitis (NASH) Segment by Application in 2023
Figure 3. Global Nonalcoholic Steatohepatitis (NASH) Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2023
Figure 8. By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 9. By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 10. By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 12. By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 14. By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 15. By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 16. US Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 20. Germany Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 21. France Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 28. China Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 32. India Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 34. Brazil Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2019-2030
Figure 37. Turkey Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2019-2030
Figure 41. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. GSK Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Roche Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
